LGALS3 and melanoma: LAG-3 and its ligands, Galectin-3 and MHC-II, exhibit high expression levels in melanoma lesions, particularly within inflamed T-cell phenotypes such as high-risk uveal melanoma, where the interaction between Galectin-3 and LAG-3 attenuates T-cell-mediated responses (35).